Xenetic Biosciences (XBIO) Return on Capital Employed (2012 - 2026)
Xenetic Biosciences' (XBIO) quarterly Return on Capital Employed came in at 33.36% in Q1 2026, up 3495.0% YoY from 0.93% in Q1 2025, and up 32.36% on a QoQ basis from 49.32% in Q4 2025.
Xenetic Biosciences (XBIO) Return on Capital Employed (2012 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 15 years of Return on Capital Employed data on file, last reported at 33.36% in Q1 2026.
- Quarterly Return on Capital Employed rose 3495.0% year-over-year to 33.36% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 33.36% (up 3495.0% YoY) and the FY2025 annual result came in at 42.53%, up 1097.0% from the prior year.
- Return on Capital Employed rose to 33.36% in Q1 2026, from 49.32% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 33.36% in Q1 2026 to a low of 80.77% in Q3 2025.
- A 5-year average of 52.05% and a median of 47.73% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed jumped 8961 bps — and 2024, when it slumped 2907 bps.
- Tracing XBIO's Return on Capital Employed over 5 years: stood at 47.73% in 2022, then advanced by 10 bps to 43.12% in 2023, then plunged by 48 bps to 63.9% in 2024, then gained by 23 bps to 49.32% in 2025, then soared by 32 bps to 33.36% in 2026.
- The last three Return on Capital Employed figures came in at 33.36% (Q1 2026), 49.32% (Q4 2025), and 80.77% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - | -40.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -40.37% |
| Mar 31, 2026 | -33.36% |
| Dec 31, 2025 | -49.32% |
| Sep 30, 2025 | -80.77% |
| Jun 30, 2025 | -69.94% |
| Mar 31, 2025 | -68.30% |
| Dec 31, 2024 | -63.90% |
| Sep 30, 2024 | -57.91% |
| Jun 30, 2024 | -65.67% |
| Mar 31, 2024 | -52.45% |
| Dec 31, 2023 | -43.12% |
| Sep 30, 2023 | -42.74% |
| Jun 30, 2023 | -36.60% |
| Mar 31, 2023 | -45.00% |
| Dec 31, 2022 | -47.73% |
| Sep 30, 2022 | -46.95% |
| Jun 30, 2022 | -47.39% |
| Mar 31, 2022 | -33.62% |
| Dec 31, 2021 | -30.04% |
| Sep 30, 2021 | -34.00% |